



DESTINY 2

SHADOWKEEP

SMALL CAP MOVERS: ImmuPharma nearly trebles in value as US deal resurrects flagship lupus drug

By CALUM MUIRHEAD AT PROACTIVE INVESTORS FOR THISISMONEY
PUBLISHED: 12:32, 29 November 2019 | UPDATED: 12:33, 29 November 2019



View comments

AIM saw a resurrection this week as small cap biotech ImmuPharma secured a deal worth almost \$100million for Lupuzor, its treatment for the autoimmune disease lupus.

US speciality drugs group Avion Pharmaceuticals will fund the \$25million in costs of a reformatted phase III clinical trial next year following the agreement of a trial design with the US Food & Drug Administration.

The UK group will receive up to \$70million of milestone payments, with \$5million due on regulatory approval of the product and a further \$65million dependent on sales targets.



© Alamy Stock Photo

On the up: ImmuPharma secures deal for Lupuzor its treatment for lupus

FTSE 100
7,346.53
-69.90 ▼

POUND
USD \$1.2906 ▼
EUR €1.1714 ▼

I want to find... ▼

Search

All articles Share prices

CHECK YOUR INVESTMENTS

- Stock market latest
- Check shares, funds and investment trusts

TOP DIY INVESTING PLATFORMS

Guidance and tools	Investing ideas
<p>Model portfolios, free fund dealing</p>	<p>Easy and most popular DIY investing platform</p>
<p>Money back in free trades</p>	<p>6 months no portfolio management fee</p>
<p>Max £30 shares and investment trust ISA fee</p>	<p>Fixed account fees, no investment limits</p>
<p>0.15% per year fee, no dealing charge</p>	<p>0.25% annual fee, no dealing charge</p>
<p>£7.50 share and</p>	<p>Online investment</p>